Chemotherapy Trial Using Etoposide, Chlorambucil, and NSAIDs for Dogs with Splenic Hemangiosarcoma

Abstract

Oral low-dose chemotherapy using a combination of etoposide, Chlorambucil, filocoxib, and piroxicam was used to perform adjuvant chemotherapy on four dogs with grade 2 or 3 splenic hemangiosarcoma. The survival times of the four cases were 307, 248, 285, and 309 days, respectively. This study highlights an alternative adjuvant chemotherapeutic modality for canine splenic hemangiosarcoma. However, further investigations in a larger number of cases are desired.